$120 Million is the total value of venBio Partners LLC's 4 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q2 2020 |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
VERONA PHARMA PLC | 15 | Q2 2022 | 22.2% |
AKERO THERAPEUTICS INC | 14 | Q3 2022 | 65.3% |
ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 73.8% |
HARMONY BIOSCIENCES HLDGS IN | 13 | Q3 2023 | 21.1% |
APELLIS PHARMACEUTICALS INC | 11 | Q2 2021 | 62.0% |
PHARVARIS N V | 11 | Q3 2023 | 25.2% |
IMPEL PHARMACEUTICALS INC | 10 | Q3 2023 | 7.3% |
ELEVATION ONCOLOGY INC | 10 | Q3 2023 | 4.2% |
VENTYX BIOSCIENCES INC | 8 | Q3 2023 | 42.7% |
PRECISION BIOSCIENCES INC | 7 | Q3 2020 | 62.0% |
View venBio Partners LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
View venBio Partners LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.